Lauren D’Angelo
Chief Operating OfficerMrs. Lauren D’Angelo, M.B.A., serves as Chief Operating Officer at Alpha Cognition Inc. since September 28, 2023 and served as its Chief Commercial Officer since May 4, 2021 until September 28, 2023. Mrs. D’Angelo has experience leading successful drug commercialization efforts across 10 therapeutic areas including neurology. She served as Vice President, Marketing and Commercial Strategy at Urovant Sciences, where she joined as employee #3 and led the commercial launch of GEMTESA®, the first new Overactive Bladder (OAB) drug treatment in more than 10 years. Prior to Urovant Sciences, Mrs. D’Angelo held leadership roles in commercial development, marketing, operations and sales at Avanir Pharmaceuticals, Medivation, Genentech and AstraZeneca. She has participated in more than10 successful pharmaceutical drug launches, six of which have become blockbuster brands, including NEXIUM®, CRESTOR®, SYMBICORT®, SEROQUEL XR®, ONGLYZA® and XTANDI®. Due to Mrs. D’Angelo’s strong track record of success, she was recognized as Medical Marketing & Media’s2017 Woman to Watch and was selected as one of Pharmaceutical Executive's Emerging Pharma Leaders for 2020. Mrs. D’Angelo received her B.S. in Management Information Systems and Finance from Florida State University and her MBA from the University of Florida.
Positions
- Company NameAlpha Cognition Inc.Stock CodeACOGPositionChief Operating OfficerColleagues
- MEMichael E. McFaddenCEO & Director
- RJRobert James WillsIndependent Chairman of the Board
- KAKenneth Anthony CawkellFounder, Consultant, Corporate Secretary & Director
- HHHenry H. DuVP of Finance & Accounting and Interim CFO
- DGDenis G. KayChief Scientific Officer
- PMPhillip MertzIndependent Director
- RKRajeev K. BakshiIndependent Director
